Lymphoma Follicular
📧 Sign up to get email alerts when something new happens for Lymphoma Follicular.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies [Phase 1, Phase 2]
A safety and efficacy trial update for JCAR017 combinations in relapsed/refractory B-cell malignancies across Phase 1 and Phase 2, completed…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma [Phase 2]
Phase 2 safety and effectiveness study of a vaccine therapy in indolent lymphoma has completed.
-
EMA withdrawal · 2023-07-10EMA Withdrawn: Lenalidomide Krka d.d. (lenalidomide hydrochloride hydrate) — Krka, d.d., Novo mesto
The EMA withdrew lenalidomide hydrochloride hydrate (Krka) from the market for multiple indications including multiple myeloma, follicular l…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial update for ASN002 in relapsed/refractory lymphoma and advanced solid tumors; the study status is TERMINATED with re…
-
EMA withdrawal · 2022-12-15EMA Withdrawn: IntronA (interferon alfa-2b) — Merck Sharp & Dohme B.V.
The European Medicines Agency has withdrawn IntronA (interferon alfa-2b) from the market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) [Phase 3]
Phase 3 trial update for Zevalin after R-CVP in previously untreated follicular lymphoma; study status terminated with results posted.
-
EMA approval · 2021-12-17EMA Authorised: Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto
EMA authorised lenalidomide Krka d.d. Novo mesto for indications including multiple myeloma and follicular lymphoma, establishing its market…
-
CLINICAL_TRIALS trial_result · 2020-04-13Clinical Trial Update: Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) [Phase 1]
Phase 1 study of ADCT-402 in relapsed or refractory B-cell lineage non-Hodgkin lymphoma completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-03-27Clinical Trial Update: Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy [Phase 3]
Phase 3 trial comparing ofatumumab-bendamustine versus bendamustine alone in rituximab-refractory indolent B-cell non-Hodgkin lymphoma was t…
-
CLINICAL_TRIALS trial_result · 2020-03-17Clinical Trial Update: A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab [Phase 1]
Phase 1 study of PF-05082566 as a single agent and with rituximab in various lymphomas; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2015-09-07Clinical Trial Update: Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) [Phase 2]
Phase 2 clinical trial update on bone marrow transplantation from partially matched donors with nonmyeloablative conditioning for various bl…
-
CLINICAL_TRIALS trial_result · 2015-08-28Clinical Trial Update: Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) [Phase 2]
Phase 2 clinical trial evaluating safety and effectiveness of an umbilical cord blood stem cell transplant for various hematologic malignanc…